Literature DB >> 17415791

Rate of clinical progression in Parkinson's disease. A prospective study.

Anette Schrag1, Richard Dodel, Annika Spottke, Bernhard Bornschein, Uwe Siebert, Niall P Quinn.   

Abstract

Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic-based sample of 145 patients over 1 year and in a community-based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow-up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow-up in the community-based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic-based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. (c) 2007 Movement Disorder Society.

Entities:  

Mesh:

Year:  2007        PMID: 17415791     DOI: 10.1002/mds.21429

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  42 in total

1.  Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Authors:  Laura B Zahodne; Michael Marsiske; Michael S Okun; Ramon L Rodriguez; Irene Malaty; Dawn Bowers
Journal:  Neuropsychology       Date:  2011-12-05       Impact factor: 3.295

Review 2.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

Review 3.  Late-stage Parkinson disease.

Authors:  Miguel Coelho; Joaquim J Ferreira
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

Review 4.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 5.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

6.  How parkinsonism influences life: the patients' point of view.

Authors:  E Martignoni; Antonietta Citterio; R Zangaglia; L Godi; C Pacchetti; C Fundarò; E Corengia; G Bono; G Nappi
Journal:  Neurol Sci       Date:  2010-11-06       Impact factor: 3.307

7.  Progression in the LRRK2-Asssociated Parkinson Disease Population.

Authors:  Rachel Saunders-Pullman; Anat Mirelman; Roy N Alcalay; Cuiling Wang; Roberto A Ortega; Deborah Raymond; Helen Mejia-Santana; Martha Orbe-Reilly; Brooke A Johannes; Avner Thaler; Laurie Ozelius; Avi Orr-Urtreger; Karen S Marder; Nir Giladi; Susan B Bressman
Journal:  JAMA Neurol       Date:  2018-03-01       Impact factor: 18.302

8.  Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.

Authors:  Jing Han Ng; Angela An Qi See; Zheyu Xu; Nicolas Kon Kam King
Journal:  J Neurol       Date:  2020-05-04       Impact factor: 4.849

9.  The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life.

Authors:  Angelo Antonini; Paolo Barone; Roberto Marconi; Letterio Morgante; Salvatore Zappulla; Francesco Ernesto Pontieri; Silvia Ramat; Maria Gabriella Ceravolo; Giuseppe Meco; Giulio Cicarelli; Massimo Pederzoli; Michela Manfredi; Roberto Ceravolo; Marco Mucchiut; Giampiero Volpe; Giovanni Abbruzzese; Edo Bottacchi; Luigi Bartolomei; Giuseppe Ciacci; Antonino Cannas; Maria Giovanna Randisi; Alfredo Petrone; Mario Baratti; Vincenzo Toni; Giovanni Cossu; Paolo Del Dotto; Anna Rita Bentivoglio; Michele Abrignani; Rossana Scala; Franco Pennisi; Rocco Quatrale; Rosa Maria Gaglio; Alessandra Nicoletti; Michele Perini; Tania Avarello; Antonio Pisani; Augusto Scaglioni; Paolo Emilio Martinelli; Francesco Iemolo; Laura Ferigo; Pasqualino Simone; Paola Soliveri; Biagio Troianiello; Domenico Consoli; Alessandro Mauro; Leonardo Lopiano; Giuseppe Nastasi; Carlo Colosimo
Journal:  J Neurol       Date:  2012-06-19       Impact factor: 4.849

10.  Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Authors:  Nir Giladi; Anthony P Nicholas; Mahnaz Asgharnejad; Elisabeth Dohin; Franz Woltering; Lars Bauer; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2016-10-19       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.